21
Hans Michael Wolff, Christoph Arth: Therapeutical system for transdermal delivery of levonorgestrel. Schwarz Pharma, Marshall Gerstein & Borun, April 29, 2003: US06555131 (17 worldwide citation)

A stable therapeutical transdermal system for the transcutaneous delivery of levonorgestrel, alone or together with other sex steroid hormones, over a long time period is disclosed. A method of producing the transdermal system that avoids the use of solvents and avoids degradation of the steroid hor ...


22
Hoffmann Hans Rainer Dr, Horstmann Michael Dr: Therapeutic transdermal system containing tulobuterol as the active ingredient.. Lohmann Therapie Syst Lts, July 31, 1991: EP0439180-A2 (17 worldwide citation)

The invention relates to a transdermal therapeutic system containing tulobuterol or one of its pharmaceutically compatible salts as active ingredient, comprising a backing layer which is essentially impermeable to active ingredient, and at least one matrix layer which contains the active ingredient ...


23
Detlef Grawe, Peter Hoesel, Wilfried Fischer: Laminates containing an active substance transdermal system. Jenapharm & Co KG, Michael J Striker, June 7, 2005: US06902741 (16 worldwide citation)

The transdermal system includes a sex hormone-containing adhesive matrix, which contains inclusions of a sex hormone in a hydrophilic non-crosslinked polymer in dissolved or dispersed form. The inclusions have a concentration of 20 to 90 percent by weight of the sex hormone, which is more than 50 pe ...


24

25
Kugelmann Heinrich, Bartholomäus Johannes: (De) Gegen missbrauch gesichertes transdermales system, (En) Transdermal system secured against misuse. Grünenthal, Kugelmann Heinrich, Bartholomäus Johannes, KUTZENBERGER Helga, November 3, 2005: WO/2005/102294 (16 worldwide citation)

(EN) The invention relates to a transdermal system which is secured against misuse. Said system contains, in addition to one or several active substances having misuse potential, at least one gel-forming agent in such an amount that it forms a gel having a minimum amount of an aqueous liquid. It als ...


26
Wilfried Fischer, Karin Klokkers, Anna Sendl Lang: Transdermal system in the form of a patch comprising a tamoxifen derivative. Hexal, Burgess Ryan & Wayne, May 18, 1999: US05904930 (15 worldwide citation)

A transdermal system in the form of a patch that comprises a tamoxifen derivative and an absorption-promoting additive for systemic administration.


27
Kugelmann Heinrich, Bartholomaeus Johannes: Transdermal system secured against misuse. Gruenenthal, January 10, 2007: EP1740161-A2 (15 worldwide citation)

The invention relates to a transdermal system which is secured against misuse. Said system contains, in addition to one or several active substances having misuse potential, at least one gel-forming agent in such an amount that it forms a gel having a minimum amount of an aqueous liquid. It also con ...


28
Arto O Urtti, Marja R Sutinen, Timo P Paronen: Transdermal drug delivery system. Finnegan Henderson Farabow Garrett and Dunner L, October 6, 1998: US05817332 (13 worldwide citation)

A controlled release transdermal system for the delivery of at least one therapeutic agent comprises: a reservoir comprising (a) the therapeutic agent in ionized form and (b) a pH adjusting agent which upon uptake of water is converted to a buffer solution and (c) a cyclized polysaccharide selected ...


29
Walter Muller, Zbigniew Czech, Gunter Simon, Joerg Reinhard: Basic active component-permeable pressure sensitive adhesive polymer material process of the production thereof and use thereof. LTS Lohmann Therapie Systeme & Co KG of Germany, Sandoz, Kalish & Gilster, October 17, 1995: US05458885 (12 worldwide citation)

A transdermal system employing a basic active component-permeable, pressure sensitive adhesive polymer material, particularly for use with basic active components for use in transdermal administration of systemically or topically acting medicaments constituted by such active components. The adhesive ...


30